CEFAZOLIN SODIUM

Search structure


Trade Names:	ANCEF ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER ANCEF IN PLASTIC CONTAINER ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER CEFAZOLIN AND DEXTROSE CEFAZOLIN IN PLASTIC CONTAINER CEFAZOLIN SODIUM KEFZOL
Synonyms:	46083 Ancef Cefacidal Cefamedin Cefamezin Cefazil Cefazolin and dextrose Cefazolin injection Cefazolin sodium Cefazolin sodium salt Cephazolin Gramaxin Kefzol NSC-291561 SK&F 41558 Totacef Zolicef
Status:	Approved (1973)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	P380M0454Z
Parent Compound:	CEFAZOLIN

Structure


InChI Key	FLKYBGKDCCEQQM-WYUVZMMLSA-M
Smile	Cc1nnc(SCC2=C(C(=O)[O-])N3C(=O)[C@@H](NC(=O)Cn4cnnn4)[C@H]3SC2)s1.[Na+]
InChI	InChI=1S/C14H14N8O4S3.Na/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21;/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26);/q;+1/p-1/t9-,12-;/m1./s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C14H13N8NaO4S3
Molecular Weight	476.5
AlogP	-0.64
Hydrogen Bond Acceptor	12.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	7.0
Polar Surface Area	156.09
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	29.0

Pharmacology

Action	Mechanism of Action	Reference
INHIBITOR	Bacterial penicillin-binding protein inhibitor	PubMed PubMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	84
Transporter Primary active transporter ATP-binding cassette ABCC subfamily	-	54200	-	-	-

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Neoplasms	3	D009369	ClinicalTrials
Hernia, Inguinal	3	D006552	ClinicalTrials
Cellulitis	2	D002481	ClinicalTrials

Related Entries

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Parent

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Immune system disorders	13.36
Skin and subcutaneous tissue disorders	12.1
Vascular disorders	9.88
General disorders and administration site conditions	7.42
Injury, poisoning and procedural complications	7.36
Gastrointestinal disorders	6.98
Nervous system disorders	5.09
Respiratory, thoracic and mediastinal disorders	5.05
Investigations	4.91
Cardiac disorders	4.44
Infections and infestations	4.31
Renal and urinary disorders	2.84
Blood and lymphatic system disorders	2.82
Pregnancy, puerperium and perinatal conditions	2.82
Hepatobiliary disorders	2.58
Metabolism and nutrition disorders	2.58
Musculoskeletal and connective tissue disorders	2.16

Cross References

Resources	Reference
ChEBI	3483
ChEMBL	CHEMBL1200523
FDA SRS	P380M0454Z
PubChem	23675322
SureChEMBL	SCHEMBL40735

CONTENTS